Aurora Cannabis Inc. (NASDAQ: ACB) Stock Competitors & Peer Comparison
See ACB's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ACB and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACB | $5.05 | -1.17% | 332M | -3.65 | -$1.38 | N/A |
| TAK | $20.84 | -0.43% | 65.3B | 14.99 | $1.39 | +3.39% |
| TEVA | $43.24 | +1.98% | 50.4B | 14.75 | $2.93 | N/A |
| HLN | $9.10 | +0.44% | 40.3B | 18.59 | $0.49 | +2.17% |
| ZTS | $82.57 | +0.13% | 33.5B | 12.55 | $6.58 | +2.58% |
| VTRS | $21.06 | +1.01% | 24.1B | 8.36 | $2.52 | +2.29% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $26.48 | -1.05% | 13.2B | 24.98 | $1.06 | N/A |
| RDY | $14.84 | -0.13% | 12.4B | 31.57 | $0.47 | +0.56% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ACB vs TAK Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, TAK has a market cap of 65.3B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while TAK trades at $20.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas TAK's P/E ratio is 14.99. In terms of profitability, ACB's ROE is -0.15%, compared to TAK's ROE of +0.05%. Regarding short-term risk, ACB is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ACB.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ACB vs TEVA Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, TEVA has a market cap of 50.4B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while TEVA trades at $43.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas TEVA's P/E ratio is 14.75. In terms of profitability, ACB's ROE is -0.15%, compared to TEVA's ROE of +0.06%. Regarding short-term risk, ACB is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for ACB.Check TEVA's competition here
Haleon plc (NYSE: HLN)
ACB vs HLN Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, HLN has a market cap of 40.3B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while HLN trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas HLN's P/E ratio is 18.59. In terms of profitability, ACB's ROE is -0.15%, compared to HLN's ROE of +0.10%. Regarding short-term risk, ACB is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for ACB.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
ACB vs ZTS Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ZTS has a market cap of 33.5B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ZTS trades at $82.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ZTS's P/E ratio is 12.55. In terms of profitability, ACB's ROE is -0.15%, compared to ZTS's ROE of +0.76%. Regarding short-term risk, ACB is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
ACB vs VTRS Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, VTRS has a market cap of 24.1B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while VTRS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas VTRS's P/E ratio is 8.36. In terms of profitability, ACB's ROE is -0.15%, compared to VTRS's ROE of -0.04%. Regarding short-term risk, ACB is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for ACB.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ACB vs ITCI Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ACB's ROE is -0.15%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ACB is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ACB.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ACB vs ELAN Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ELAN has a market cap of 13.2B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ELAN trades at $26.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ELAN's P/E ratio is 24.98. In terms of profitability, ACB's ROE is -0.15%, compared to ELAN's ROE of -0.02%. Regarding short-term risk, ACB is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ACB vs RDY Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, RDY has a market cap of 12.4B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while RDY trades at $14.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas RDY's P/E ratio is 31.57. In terms of profitability, ACB's ROE is -0.15%, compared to RDY's ROE of +0.07%. Regarding short-term risk, ACB is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for ACB.Check RDY's competition here
Catalent, Inc. (NYSE: CTLT)
ACB vs CTLT Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ACB's ROE is -0.15%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ACB is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ACB.Check CTLT's competition here
Alkermes plc (NASDAQ: ALKS)
ACB vs ALKS Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ALKS has a market cap of 8B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ALKS trades at $47.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ALKS's P/E ratio is 50.41. In terms of profitability, ACB's ROE is -0.15%, compared to ALKS's ROE of -0.00%. Regarding short-term risk, ACB is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ACB vs AMRX Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, AMRX has a market cap of 7.6B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while AMRX trades at $21.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas AMRX's P/E ratio is 24.12. In terms of profitability, ACB's ROE is -0.15%, compared to AMRX's ROE of +1.32%. Regarding short-term risk, ACB is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for ACB.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ACB vs LNTH Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while LNTH trades at $101.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas LNTH's P/E ratio is 17.08. In terms of profitability, ACB's ROE is -0.15%, compared to LNTH's ROE of +0.22%. Regarding short-term risk, ACB is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ACB.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ACB vs INDV Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while INDV trades at $36.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas INDV's P/E ratio is 9.94. In terms of profitability, ACB's ROE is -0.15%, compared to INDV's ROE of -3.53%. Regarding short-term risk, ACB is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for ACB.Check INDV's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ACB vs BHC Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, BHC has a market cap of 3.1B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while BHC trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas BHC's P/E ratio is 2.13. In terms of profitability, ACB's ROE is -0.15%, compared to BHC's ROE of +0.59%. Regarding short-term risk, ACB is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for ACB.Check BHC's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ACB vs RGC Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while RGC trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas RGC's P/E ratio is -541.00. In terms of profitability, ACB's ROE is -0.15%, compared to RGC's ROE of -1.61%. Regarding short-term risk, ACB is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for ACB.Check RGC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ACB vs HCM Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, HCM has a market cap of 2.6B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while HCM trades at $15.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas HCM's P/E ratio is 145.84. In terms of profitability, ACB's ROE is -0.15%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ACB is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for ACB.Check HCM's competition here
Perrigo Company plc (NYSE: PRGO)
ACB vs PRGO Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, PRGO has a market cap of 2.3B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while PRGO trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas PRGO's P/E ratio is 6.62. In terms of profitability, ACB's ROE is -0.15%, compared to PRGO's ROE of -0.68%. Regarding short-term risk, ACB is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for ACB.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ACB vs DCPH Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ACB's ROE is -0.15%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ACB is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ACB.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ACB vs AVDL Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ACB's ROE is -0.15%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, ACB is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ACB.Check AVDL's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ACB vs ETON Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ETON has a market cap of 2B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ETON trades at $68.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ETON's P/E ratio is 180.00. In terms of profitability, ACB's ROE is -0.15%, compared to ETON's ROE of +1.05%. Regarding short-term risk, ACB is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ETON's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
ACB vs TRLV Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, TRLV has a market cap of 1.9B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while TRLV trades at $11.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas TRLV's P/E ratio is -4.57. In terms of profitability, ACB's ROE is -0.15%, compared to TRLV's ROE of -0.46%. Regarding short-term risk, ACB is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for ACB.Check TRLV's competition here
Embecta Corp. (NASDAQ: EMBCV)
ACB vs EMBCV Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ACB's ROE is -0.15%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ACB is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ACB.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ACB vs DVAX Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ACB's ROE is -0.15%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, ACB is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ACB.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
ACB vs ALVO Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ALVO trades at $4.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ALVO's P/E ratio is -8.34. In terms of profitability, ACB's ROE is -0.15%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ACB is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ALVO's competition here
Supernus, Inc. (NASDAQ: SUPN)
ACB vs SUPN Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, SUPN has a market cap of 1.7B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while SUPN trades at $29.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas SUPN's P/E ratio is -38.89. In terms of profitability, ACB's ROE is -0.15%, compared to SUPN's ROE of -3.53%. Regarding short-term risk, ACB is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for ACB.Check SUPN's competition here
Alvotech (NASDAQ: ALVOW)
ACB vs ALVOW Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ALVOW has a market cap of 1.7B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ALVOW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ALVOW's P/E ratio is 26.59. In terms of profitability, ACB's ROE is -0.15%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, ACB is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ALVOW's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ACB vs ANIP Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ANIP trades at $71.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ANIP's P/E ratio is 8.65. In terms of profitability, ACB's ROE is -0.15%, compared to ANIP's ROE of +0.20%. Regarding short-term risk, ACB is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ACB vs TARO Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas TARO's P/E ratio is 30.05. In terms of profitability, ACB's ROE is -0.15%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ACB is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ACB.Check TARO's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ACB vs PCRX Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, PCRX has a market cap of 1.5B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while PCRX trades at $36.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas PCRX's P/E ratio is 14.02. In terms of profitability, ACB's ROE is -0.15%, compared to PCRX's ROE of +0.06%. Regarding short-term risk, ACB is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ACB.Check PCRX's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ACB vs PAHC Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while PAHC trades at $35.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas PAHC's P/E ratio is 12.00. In terms of profitability, ACB's ROE is -0.15%, compared to PAHC's ROE of +0.27%. Regarding short-term risk, ACB is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for ACB.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
ACB vs CRON Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while CRON trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas CRON's P/E ratio is 17.67. In terms of profitability, ACB's ROE is -0.15%, compared to CRON's ROE of +0.05%. Regarding short-term risk, ACB is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for ACB.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ACB vs AMPH Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while AMPH trades at $28.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas AMPH's P/E ratio is 9.76. In terms of profitability, ACB's ROE is -0.15%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, ACB is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for ACB.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ACB vs HROW Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while HROW trades at $29.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas HROW's P/E ratio is -29.67. In terms of profitability, ACB's ROE is -0.15%, compared to HROW's ROE of -0.91%. Regarding short-term risk, ACB is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for ACB.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ACB vs PETQ Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ACB's ROE is -0.15%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ACB is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ACB.Check PETQ's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ACB vs IRWD Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, IRWD has a market cap of 806.2M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while IRWD trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas IRWD's P/E ratio is 6.24. In terms of profitability, ACB's ROE is -0.15%, compared to IRWD's ROE of -0.93%. Regarding short-term risk, ACB is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for ACB.Check IRWD's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ACB vs COLL Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, COLL has a market cap of 771M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while COLL trades at $24.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas COLL's P/E ratio is 3.11. In terms of profitability, ACB's ROE is -0.15%, compared to COLL's ROE of +0.12%. Regarding short-term risk, ACB is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for ACB.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
ACB vs EVO Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, EVO has a market cap of 600.3M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while EVO trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas EVO's P/E ratio is -2.39. In terms of profitability, ACB's ROE is -0.15%, compared to EVO's ROE of -0.26%. Regarding short-term risk, ACB is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for ACB.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ACB vs BDSI Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ACB's ROE is -0.15%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ACB is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ACB.Check BDSI's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ACB vs TKNO Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, TKNO has a market cap of 541M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while TKNO trades at $8.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas TKNO's P/E ratio is -27.81. In terms of profitability, ACB's ROE is -0.15%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ACB is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ACB.Check TKNO's competition here
Evolus, Inc. (NASDAQ: EOLS)
ACB vs EOLS Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, EOLS has a market cap of 491.1M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while EOLS trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas EOLS's P/E ratio is -23.50. In terms of profitability, ACB's ROE is -0.15%, compared to EOLS's ROE of +1.03%. Regarding short-term risk, ACB is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for ACB.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
ACB vs KMDA Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, KMDA has a market cap of 469.1M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while KMDA trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas KMDA's P/E ratio is 21.39. In terms of profitability, ACB's ROE is -0.15%, compared to KMDA's ROE of +0.09%. Regarding short-term risk, ACB is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for ACB.Check KMDA's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ACB vs AQST Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, AQST has a market cap of 450M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while AQST trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas AQST's P/E ratio is -5.51. In terms of profitability, ACB's ROE is -0.15%, compared to AQST's ROE of +2.55%. Regarding short-term risk, ACB is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for ACB.Check AQST's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
ACB vs EBS Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, EBS has a market cap of 310.5M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while EBS trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas EBS's P/E ratio is 4.19. In terms of profitability, ACB's ROE is -0.15%, compared to EBS's ROE of -0.61%. Regarding short-term risk, ACB is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for ACB.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ACB vs ALIM Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ACB's ROE is -0.15%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ACB is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ACB.Check ALIM's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ACB vs TLRY Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, TLRY has a market cap of 291.9M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while TLRY trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas TLRY's P/E ratio is -1.86. In terms of profitability, ACB's ROE is -0.15%, compared to TLRY's ROE of -0.10%. Regarding short-term risk, ACB is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for ACB.Check TLRY's competition here
Landec Corporation (NASDAQ: LNDC)
ACB vs LNDC Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ACB's ROE is -0.15%, compared to LNDC's ROE of +5.75%. Regarding short-term risk, ACB is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for ACB.Check LNDC's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ACB vs CGC Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, CGC has a market cap of 256.1M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while CGC trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas CGC's P/E ratio is -1.35. In terms of profitability, ACB's ROE is -0.15%, compared to CGC's ROE of -0.39%. Regarding short-term risk, ACB is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for ACB.Check CGC's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ACB vs LFCR Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, LFCR has a market cap of 242.6M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while LFCR trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas LFCR's P/E ratio is -5.04. In terms of profitability, ACB's ROE is -0.15%, compared to LFCR's ROE of +3.82%. Regarding short-term risk, ACB is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ACB.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
ACB vs TYHT Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ACB's ROE is -0.15%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ACB is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for ACB.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ACB vs SIGA Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, SIGA has a market cap of 225.6M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while SIGA trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas SIGA's P/E ratio is 11.63. In terms of profitability, ACB's ROE is -0.15%, compared to SIGA's ROE of +0.00%. Regarding short-term risk, ACB is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for ACB.Check SIGA's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ACB vs REPH Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas REPH's P/E ratio is -8.04. In terms of profitability, ACB's ROE is -0.15%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ACB is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ACB.Check REPH's competition here
Glass House Brands Inc (NYSE: GLAS)
ACB vs GLAS Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, GLAS has a market cap of 166.8M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while GLAS trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas GLAS's P/E ratio is -3.39. In terms of profitability, ACB's ROE is -0.15%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ACB is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for ACB.Check GLAS's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ACB vs THTX Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas THTX's P/E ratio is -28.83. In terms of profitability, ACB's ROE is -0.15%, compared to THTX's ROE of +0.36%. Regarding short-term risk, ACB is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ACB.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ACB vs ASRT Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ACB's ROE is -0.15%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ACB is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ACB.Check ASRT's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ACB vs ORGO Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ORGO has a market cap of 136.3M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ORGO trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ORGO's P/E ratio is 35.00. In terms of profitability, ACB's ROE is -0.15%, compared to ORGO's ROE of -0.46%. Regarding short-term risk, ACB is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ORGO's competition here
Journey Medical Corporation (NASDAQ: DERM)
ACB vs DERM Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, DERM has a market cap of 125.3M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while DERM trades at $4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas DERM's P/E ratio is -20.18. In terms of profitability, ACB's ROE is -0.15%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ACB is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for ACB.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ACB vs CRDL Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, CRDL has a market cap of 121.9M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while CRDL trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas CRDL's P/E ratio is -4.02. In terms of profitability, ACB's ROE is -0.15%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ACB is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for ACB.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
ACB vs OGI Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, OGI has a market cap of 120.4M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while OGI trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas OGI's P/E ratio is 1.92. In terms of profitability, ACB's ROE is -0.15%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ACB is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for ACB.Check OGI's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ACB vs SCTL Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ACB's ROE is -0.15%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ACB is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ACB.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
ACB vs BGM Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, BGM has a market cap of 110.4M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while BGM trades at $8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas BGM's P/E ratio is -1.81. In terms of profitability, ACB's ROE is -0.15%, compared to BGM's ROE of -0.05%. Regarding short-term risk, ACB is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ACB.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
ACB vs PROC Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas PROC's P/E ratio is 1.53. In terms of profitability, ACB's ROE is -0.15%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ACB is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ACB.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ACB vs OPTN Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ACB's ROE is -0.15%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ACB is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ACB.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ACB vs ZOM Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ACB's ROE is -0.15%, compared to ZOM's ROE of -0.14%. Regarding short-term risk, ACB is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ZOM's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ACB vs CPIX Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, CPIX has a market cap of 91.7M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while CPIX trades at $6.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas CPIX's P/E ratio is -15.30. In terms of profitability, ACB's ROE is -0.15%, compared to CPIX's ROE of +2.03%. Regarding short-term risk, ACB is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ACB.Check CPIX's competition here
Upexi, Inc. (NASDAQ: GRVI)
ACB vs GRVI Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ACB's ROE is -0.15%, compared to GRVI's ROE of +114.74%. Regarding short-term risk, ACB is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ACB.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ACB vs ZYBT Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ZYBT has a market cap of 71.6M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ZYBT trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ZYBT's P/E ratio is -7.55. In terms of profitability, ACB's ROE is -0.15%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, ACB is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ACB vs ZYNE Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ACB's ROE is -0.15%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ACB is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ACB vs SSIC Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ACB's ROE is -0.15%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ACB is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for ACB.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ACB vs VLNS Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ACB's ROE is -0.15%, compared to VLNS's ROE of N/A. Regarding short-term risk, ACB is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for ACB.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
ACB vs DRRX Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ACB's ROE is -0.15%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, ACB is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ACB.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
ACB vs TLPH Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, TLPH has a market cap of 54.5M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while TLPH trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas TLPH's P/E ratio is -3.89. In terms of profitability, ACB's ROE is -0.15%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ACB is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for ACB.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
ACB vs INCR Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, INCR has a market cap of 51.2M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while INCR trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas INCR's P/E ratio is -4.16. In terms of profitability, ACB's ROE is -0.15%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ACB is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for ACB.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ACB vs JUPW Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ACB's ROE is -0.15%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ACB is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ACB.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ACB vs QLI Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas QLI's P/E ratio is -4.92. In terms of profitability, ACB's ROE is -0.15%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ACB is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ACB.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
ACB vs HEXO Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ACB's ROE is -0.15%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ACB is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ACB.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ACB vs RMTI Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while RMTI trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas RMTI's P/E ratio is -5.28. In terms of profitability, ACB's ROE is -0.15%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ACB is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ACB.Check RMTI's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ACB vs SHPH Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, SHPH has a market cap of 25M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while SHPH trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas SHPH's P/E ratio is -0.24. In terms of profitability, ACB's ROE is -0.15%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, ACB is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ACB.Check SHPH's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ACB vs CYTH Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ACB's ROE is -0.15%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ACB is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ACB.Check CYTH's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ACB vs CPHI Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, CPHI has a market cap of 22.7M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while CPHI trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas CPHI's P/E ratio is -1.23. In terms of profitability, ACB's ROE is -0.15%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ACB is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for ACB.Check CPHI's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ACB vs TXMD Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, TXMD has a market cap of 20.8M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while TXMD trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas TXMD's P/E ratio is 91.70. In terms of profitability, ACB's ROE is -0.15%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ACB is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for ACB.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ACB vs AYTU Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, AYTU has a market cap of 20M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while AYTU trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas AYTU's P/E ratio is -1.56. In terms of profitability, ACB's ROE is -0.15%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, ACB is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for ACB.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ACB vs EVOK Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ACB's ROE is -0.15%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, ACB is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ACB.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ACB vs ACRX Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ACB's ROE is -0.15%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ACB is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ACRX's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ACB vs OPTH Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, OPTH has a market cap of 13.7M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while OPTH trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas OPTH's P/E ratio is -1.54. In terms of profitability, ACB's ROE is -0.15%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ACB is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ACB.Check OPTH's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ACB vs AGRX Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ACB's ROE is -0.15%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ACB is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for ACB.Check AGRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
ACB vs CABR Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, CABR has a market cap of 8.6M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while CABR trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas CABR's P/E ratio is -1.21. In terms of profitability, ACB's ROE is -0.15%, compared to CABR's ROE of -3.86%. Regarding short-term risk, ACB is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for ACB.Check CABR's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
ACB vs INM Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, INM has a market cap of 8.5M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while INM trades at $15.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas INM's P/E ratio is -5.07. In terms of profitability, ACB's ROE is -0.15%, compared to INM's ROE of -3.04%. Regarding short-term risk, ACB is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for ACB.Check INM's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ACB vs NLTX Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ACB's ROE is -0.15%, compared to NLTX's ROE of -0.44%. Regarding short-term risk, ACB is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for ACB.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ACB vs LCI Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas LCI's P/E ratio is -0.04. In terms of profitability, ACB's ROE is -0.15%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ACB is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ACB.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ACB vs ADMP Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ACB's ROE is -0.15%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ACB is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for ACB.Check ADMP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ACB vs SNOA Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, SNOA has a market cap of 5.9M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while SNOA trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas SNOA's P/E ratio is -1.12. In terms of profitability, ACB's ROE is -0.15%, compared to SNOA's ROE of -0.36%. Regarding short-term risk, ACB is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for ACB.Check SNOA's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ACB vs SBFM Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, SBFM has a market cap of 5.8M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while SBFM trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas SBFM's P/E ratio is -0.45. In terms of profitability, ACB's ROE is -0.15%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, ACB is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for ACB.Check SBFM's competition here
Mallinckrodt plc (AMEX: MNK)
ACB vs MNK Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas MNK's P/E ratio is -0.44. In terms of profitability, ACB's ROE is -0.15%, compared to MNK's ROE of -0.33%. Regarding short-term risk, ACB is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ACB.Check MNK's competition here
cbdMD, Inc. (AMEX: YCBD)
ACB vs YCBD Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, YCBD has a market cap of 4.4M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while YCBD trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas YCBD's P/E ratio is -0.97. In terms of profitability, ACB's ROE is -0.15%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ACB is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ACB.Check YCBD's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ACB vs FLGC Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ACB's ROE is -0.15%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ACB is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ACB.Check FLGC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
ACB vs SBFMW Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, SBFMW has a market cap of 4.2M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while SBFMW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas SBFMW's P/E ratio is N/A. In terms of profitability, ACB's ROE is -0.15%, compared to SBFMW's ROE of -0.24%. Regarding short-term risk, ACB is more volatile compared to SBFMW. This indicates higher risk in terms of short-term price fluctuations for ACB.Check SBFMW's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ACB vs GELS Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, GELS has a market cap of 3.9M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while GELS trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas GELS's P/E ratio is -0.96. In terms of profitability, ACB's ROE is -0.15%, compared to GELS's ROE of -0.36%. Regarding short-term risk, ACB is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for ACB.Check GELS's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ACB vs PLXP Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ACB's ROE is -0.15%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ACB is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ACB.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
ACB vs ATNX Comparison November 2026
Aurora Cannabis Inc. (NASDAQ: ACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 332M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ACB is priced at $5.05 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of -3.65, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ACB's ROE is -0.15%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ACB is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ACB.Check ATNX's competition here